[Federal Register Volume 78, Number 54 (Wednesday, March 20, 2013)]
[Notices]
[Page 17231]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-06328]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances, Notice of Registration, Watson 
Pharma, Inc.

    By Notice dated November 5, 2012, and published in the Federal 
Register on November 13, 2012, 77 FR 67675, Watson Pharma, Inc., 2455 
Wardlow Road, Corona, California 92880-2882, made application to the 
Drug Enforcement Administration (DEA) to be registered as an importer 
of the following basic classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Amphetamine (1100).........................  II
Methylphenidate (1724).....................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
------------------------------------------------------------------------

    The company plans to import the listed controlled substances for 
analytical testing and clinical trials.
    The import of the above listed basic classes of controlled 
substances will be granted only for analytical testing and clinical 
trials. This authorization does not extend to the import of a finished 
FDA approved or non-approved dosage form for commercial distribution in 
the United States.
    One comment objecting to the granting of registration as an 
importer of the basic class of controlled substance listed to this 
applicant and a request for a hearing were received on December 31, 
2012. The objection and request for a hearing were withdrawn.
    DEA has considered the factors in 21 U.S.C. 823(a) and Sec.  952(a) 
and determined that the registration of Watson Pharma, Inc., to import 
the basic classes of controlled substances is consistent with the 
public interest and with United States obligations under international 
treaties, conventions, or protocols in effect on May 1, 1971. DEA has 
investigated Watson Pharma, Inc., to ensure that the company's 
registration is consistent with the public interest. The investigation 
has included inspection and testing of the company's physical security 
systems; verification of the company's compliance with state and local 
laws; and a review of the company's background and history.
    Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in 
accordance with 21 CFR 1301.34, the above named company is granted 
registration as an importer of the basic classes of controlled 
substances listed.

    Dated: March 12, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-06328 Filed 3-19-13; 8:45 am]
BILLING CODE 4410-09-P